Antimicrobial Agents and Chemotherapy

View all AAC RSS

Impact of the double deletion ΔG242-T243 in KPC-2 in the effectiveness of ceftazidime-avibactam and imipenem-relebactam
by Florencia BrunettiGabriel GutkindLin GaoShozeb HaiderRobert A. BonomoPablo Power1Universidad de Buenos Aires, Instituto de Investigaciones en Bacteriología y Virología Molecular (IBaViM), Facultad de Farmacia y Bioquímica, Buenos Aires, Argentina2Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET)62873https://ror.org/03cqe8w59, Buenos Aires, Argentina3UCL School of Pharmacy371646, London, United Kingdom4Prince Fahad Bin Sultan Chair for Biomedical Research (PFSCBR), University of Tabuk125900https://ror.org/04yej8x59, Tabuk, Saudi Arabia5UCL Centre for Advanced Research Computing392547, London, United Kingdom6Research Service, Louis Stokes Cleveland Department of Veterans Affairs Medical Center465630https://ror.org/05dbx6743, Cleveland, Ohio, USA7Department of Medicine, Case Western Reserve University School of Medicine12304https://ror.org/0377srw41, Cleveland, Ohio, USA8Clinician Scientist Investigator, Louis Stokes Cleveland Department of Veterans Affairs Medical Center20083https://ror.org/05dbx6743, Cleveland, Ohio, USA9Department of Molecular Biology and Microbiology, Case Western Reserve University School of Medicine12304https://ror.org/0377srw41, Cleveland, Ohio, USA10Department of Pharmacology, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA11Department of Biochemistry, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA12Department of Proteomics and Bioinformatics, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA13CWRU-Cleveland VAMC Center for Antimicrobial Resistance and Epidemiology (Case VA CARES), Cleveland, Ohio, USALaurent Poirel on May 5, 2025 at 7:00 am
Antimicrobial susceptibility and genetic mechanisms of resistance of Ureaplasma isolates in North America between 2012 and 2023
by Joshua T. WaitesDonna M. CrabbAmy E. RatliffKen B. WaitesLi Xiao1Departments of Pathology, The University of Alabama at Birmingham189178https://ror.org/008s83205, Birmingham, Alabama, USA2Department of Medicine, The University of Alabama at Birmingham164494https://ror.org/008s83205, Birmingham, Alabama, USASarah Doernberg on May 5, 2025 at 7:00 am
Determining an appropriate fosfomycin (ZTI-01) dosing regimen in pneumonia patients by utilizing minimal PBPK modeling and target attainment analysis
by Jomana Al HrootJoshua ReederXuanzhen YuanKenan GuEmmanuel B. WalterLindsay BooleLoretta G. QueGuohua An1Department of Pharmaceutical Sciences and Experimental Therapeutics, College of Pharmacy, University of Iowa15509https://ror.org/036jqmy94, Iowa City, Iowa, USA2Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases540429https://ror.org/043z4tv69, Bethesda, Maryland, USA3Duke Human Vaccine Institute, Duke University School of Medicine12277, Durham, North Carolina, USA4Department of Pediatrics, Duke University School of Medicine12277, Durham, North Carolina, USA5Division of Pulmonary, Allergy, and Critical Care Medicine, Duke University of School of Medicine12277, Durham, North Carolina, USABenjamin P. Howden on May 5, 2025 at 7:00 am
Population pharmacokinetics of intravenous fosfomycin: dose optimization for critically ill patients with and without kidney replacement therapy
by Katharina M. GötzSascha KreuerAnke-Katrin VolzSuzanne L. ParkerJason A. RobertsGeorge DimopoulosThomas DimskiDetlef Kindgen-MillesLisa K.V. BeucheJan T. KielsteinThorsten Lehr1Saarmetrics GmbH, Saarland University9379https://ror.org/01jdpyv68, Saarbrücken, Germany2Department of Clinical Pharmacy, Saarland University9379https://ror.org/01jdpyv68, Saarbrücken, Germany3Department of Anaesthesiology, Intensive Care and Pain Therapy, Saarland University Medical Center and Saarland University Faculty of Medicine197751https://ror.org/01jdpyv68, Homburg, Germany4University of Queensland Centre for Clinical Research, Faculty of Medicine,The University of Queenslandhttps://ror.org/00rqy9422, Brisbane, Queensland, Australia5Herston Infectious Diseases Institute (HeIDI), Metro North Health, Brisbane, Australia6Departments of Pharmacy and Intensive Care Medicine, Royal Brisbane and Women’s Hospitalhttps://ror.org/05p52kj31, Brisbane, Australia7UR UM 103, University of Montpellier, Division of Anesthesia Critical Care and Emergency and Pain Medicine, Nimes University Hospital, Nimes, France8Third Department of Critical Care Medicine, National and Kapodistrian University of Athens, Medical School68993https://ror.org/04gnjpq42, Athens, Greece9Department of Anesthesiology, University Hospital Düsseldorf, Heinrich Heine University Düsseldorfhttps://ror.org/024z2rq82, Düsseldorf, Germany10Medical Clinic V (Nephrology, Rheumatology, Blood Purification), Academic Teaching Hospital Braunschweig, Braunschweig, GermanyJames E. Leggett on May 5, 2025 at 7:00 am
Regulation of phosphatidylinositol-(4,5)-bisphosphate and active-Rho1p levels and distribution is crucial for correct spatio-temporal cytokinesis and echinocandin responses in Candida albicans
by Hassan BadraneM. Hong NguyenCornelius J. Clancy1Department of of Medicine, Division of Infectious Diseases, University of Pittsburgh6614https://ror.org/01an3r305, Pittsburgh, Pennsylvania, USA2V.A. Pittsburgh Healthcare System, Pittsburgh, Pennsylvania, USAAndreas H. Groll on May 5, 2025 at 7:00 am
Ex vivo assessment and simulation to guide cefepime-taniborbactam dosing recommendations for patients receiving continuous renal replacement therapy
by Aliaa FouadCole McGrathEcem BuyukyanboluJoseph L. Kuti1Center for Anti-Infective Research and Development, Hartford Hospital23893https://ror.org/00gt5xe03, , Hartford, Connecticut, USAJames E. Leggett on May 5, 2025 at 7:00 am
Intermittent suppressive posaconazole therapy is ineffective at mitigating cardiac and digestive tract pathologies in an experimental model of chronic Chagas disease
by Shiromani JayawardhanaFrancisco OlmoAmanda Fortes FranciscoArchie A. KhanMichael D. LewisMartin C. TaylorJohn M. Kelly1Department of Infection Biology, London School of Hygiene and Tropical Medicinehttps://ror.org/00a0jsq62, London, UK2Department of Parasitology, Faculty of Sciences, University of Granada16741https://ror.org/04njjy449, Granada, SpainAudrey Odom John on May 5, 2025 at 7:00 am
Comparative effectiveness and safety of colistin-based versus high-dose ampicillin/sulbactam-based combination therapy for nosocomial pneumonia caused by carbapenem-resistant Acinetobacter baumannii
by Jaehoon LeeImchang LeeKi-Byung LeeSeung Soon Lee1Hallym University College of Medicine96664https://ror.org/03sbhge02, Chuncheon, Gangwon, South Korea2Department of Life Science, Multidisciplinary Genome Institute, Hallym University26727https://ror.org/03sbhge02, Chuncheon, Gangwon, South Korea3Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Hallym University Chuncheon Sacred Heart Hospital, Hallym University College of Medicine96664https://ror.org/03sbhge02, Chuncheon, Gangwon, South Korea4Division of Infectious Diseases, Department of Internal Medicine, Hallym University Chuncheon Sacred Heart Hospital, Hallym University College of Medicine96664https://ror.org/03sbhge02, Chuncheon, Gangwon, South KoreaPranita D. Tamma on April 23, 2025 at 7:00 am
Prevalence and characteristics of tigecycline- and carbapenem-resistant adeN-truncated Acinetobacter baumannii: a genomic epidemiological analysis
by Ying ZhangBeibei ZhouJingchun KongPanjie HuHaifeng LiuDeyi ZhaoJianzhong YeQingxia FuTieli ZhouChangrui Qian1Department of Clinical Laboratory, Key Laboratory of Clinical Laboratory Diagnosis and Translational Research of Zhejiang Province, The First Affiliated Hospital of Wenzhou Medical University89657https://ror.org/03cyvdv85, Wenzhou, Zhejiang, China2School of Laboratory Medicine and Life Science, Wenzhou Medical University214181https://ror.org/00rd5t069, Wenzhou, Zhejiang, ChinaPranita D. Tamma on April 23, 2025 at 7:00 am
The KasA inhibitor JSF-3285 improves the sterilizing activity of bedaquiline-pretomanid-containing regimens in a mouse model of tuberculosis
by Heena SoniSandeep TyagiKishor ManeAnil M. ShelkePradeep KumarFirat KayaDavid AllandMatthew ZimmermanJoel S. FreundlichEric L. Nuermberger1Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University1466https://ror.org/00za53h95, Baltimore, Maryland, USA2Department of Pharmacology, Physiology, and Neuroscience, Rutgers University–New Jersey Medical School67206, Newark, New Jersey, USA3Division of Infectious Disease, Department of Medicine and the Ruy V. Lourenco Center for the Study of Emerging and Re-emerging Pathogens, Rutgers University–New Jersey Medical School, Newark, New Jersey, USA4Public Health Research Institute, Rutgers University–New Jersey Medical School, Newark, New Jersey, USA5Center for Discovery & Innovation, Hackensack Meridian Health, Nutley, New Jersey, USASean Wasserman on April 23, 2025 at 7:00 am
Population pharmacokinetics and dosing optimization of teicoplanin in renal transplant patients
by Yangang ZhouJiawei PengPing XuFeng WangJun XiHedong ZhangShanbiao HuHan YanLiang TanHualin CaiBikui ZhangGongbin Lan1Department of Pharmacy, The Second Xiangya Hospital, Central South University620666https://ror.org/053v2gh09, Changsha, Hunan, China2Institute of Clinical Pharmacy, Central South University12570https://ror.org/00f1zfq44, Changsha, Hunan, China3Department of Kidney Transplantation, The Second Xiangya Hospital, Central South University612365https://ror.org/053v2gh09, Changsha, Hunan, China4Hunan Demeter Instruments Co., Ltd., Changsha, Hunan, China5Clinical Research Center for Organ Transplantation in Hunan Province, Changsha, Hunan, ChinaJames E. Leggett on April 23, 2025 at 7:00 am
Studies in vitro e in vivo of phage therapy medical products (PTMPs) Targeting Clinical Strains of Klebsiella pneumoniae belonging to the clone ST512
by Inés BleriotLucía BlascoPatricia Fernández-GrelaLaura Fernández-GarcíaLucia ArmánClara IbargurenConcha Ortiz-CartagenaAntonio Barrio-PujanteJosé Ramón PañoJesús Oteo-IglesiasMaría Tomás1Departamento de Microbiología-Hospital A Coruña (HUAC), Grupo de Microbiología Traslacional y Multidisciplinar (Micro-TM), A Coruña, Spain2Grupo de Estudio de Mecanismos de Acción y Resistencia a los Antimicrobianos (GEMARA) en nombre de la Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (SEIMC)376357, Madrid, Spain3Hospital Clínico Universitario “Lozano Blesa”, Instituto de Investigación Sanitaria Aragón507423https://ror.org/03njn4610, Zaragoza, Aragon, Spain4CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III38176https://ror.org/00ca2c886, Madrid, Community of Madrid, Spain5MEPRAM, Proyecto de Medicina de Precisión contra las resistencias Antimicrobianas, Madrid, Spain6Laboratorio de Referencia e Investigación de Resistencias Antibióticas e Infecciones Sanitarias, Centro Nacional de Microbiología, Instituto de Salud Carlos III38176https://ror.org/00ca2c886, Madrid, SpainLaurent Poirel on April 23, 2025 at 7:00 am
Case Commentary: A herculean effort for Mycobacterium heraklionense—localized azithromycin bead pharmacokinetics
by Shemual TsaiKevin Grimes1Department of Pharmacy, Houston Methodist Hospital23534, Houston, Texas, USA2Division of Infectious Diseases, Department of Internal Medicine, Houston Methodist Hospital23534, Houston, Texas, USACesar A. Arias on April 23, 2025 at 7:00 am
Plasmodium falciparum Kelch-13 artemisinin partial resistance markers in Fort Portal, Western Uganda, 2024
by Welmoed van LoonEmma SchallenbergEmmanuel MandePatrick MusinguziPaul NgobiSharon AtukundaJohn RubaihayoFrank P. Mockenhaupt1Institute of International Health, Charité Center for Global Health, Charité-Universitaetsmedizin Berlin425077, Berlin, Germany2Infectious Diseases Institute, College of Health Sciences, Makerere University242941https://ror.org/02caa0269, Kampala, Central Region, Uganda3Fort Portal Regional Referral Hospital279378https://ror.org/02rpzg225, Fort Portal, Western Region, Uganda4Department of Public Health, Mountains of the Moon University187215https://ror.org/03s5r1026, Fort Portal, Western Region, UgandaAudrey Odom John on April 23, 2025 at 7:00 am
Evaluation of shorter versus longer antifungal treatment durations for Candida spp. urinary tract infections among hospitalized adults
by Jacob C. GovelRobert W. SeaburyElizabeth A. Asiago-ReddyRamiro L. GutierrezKatie A. ParselsWesley D. Kufel1State University of New York at Binghamton School of Pharmacy and Pharmaceutical Sciences465824https://ror.org/008rmbt77, Binghamton, New York, USA2State University of New York Upstate University Hospital, Syracuse, New York, USA3State University of New York Upstate Medical Universityhttps://ror.org/040kfrw16, Syracuse, New York, USAPranita D. Tamma on April 22, 2025 at 7:00 am
Emergence of KPC-8-producing K. pneumoniae infection without prior exposure to ceftazidime/avibactam: the threat of de novo infections by ceftazidime/avibactam-resistant KPC variants
by María Alejandra Mateo-VargasSalud Rodríguez-PallaresJorge Arca-SuárezLorena López-CereroManuel Rodríguez-IglesiasFátima Galán-Sánchez1Departamento de Biomedicina, Biotecnología y Salud Pública, Universidad de Cádizhttps://ror.org/04mxxkb11, Cadiz, Spain2Servicio de Microbiología and Instituto de Investigación Biomédica A Coruña (INIBIC), Complexo Hospitalario Universitario A Coruña, A Coruña (Spain)https://ror.org/044knj408, A Coruña, Spain3CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos IIIhttps://ror.org/00ca2c886, Madrid, Spain4Unidad Clínica de Enfermedades Infecciosas y Microbiología, Hospital Universitario Virgen Macarena, Instituto de Biomedicina de Sevilla IBIShttps://ror.org/016p83279, Seville, Spain5Departamento de Microbiología, Universidad de Sevillahttps://ror.org/03yxnpp24, Seville, Spain6Servicio de Microbiología and Instituto de Innovación e Investigación Biomédica de Cádiz (INIBICA), Hospital Universitario Puerta del Marhttps://ror.org/040xzg562, Cadiz, SpainAlessandra Carattoli on April 22, 2025 at 7:00 am
The ahpC c−54t compensatory mutation is not always a valid surrogate for isoniazid resistance in Mycobacterium tuberculosis
by Viktória SzélJody E. PhelanSophia B. GeorghiouDavid L. DolingerTaane G. ClarkStefan NiemannLilla K. LőrincziClaudio U. Köser1National Reference Laboratory for Mycobacteriology, National Koranyi Institute of Pulmonology117038, Budapest, Hungary2Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine4906https://ror.org/00a0jsq62, London, United Kingdom3End TB Dx Consulting LLC12220, San Diego, California, USA4DLD IVD Consulting LLC, Medway, Massachusetts, USA5Molecular and Experimental Mycobacteriology, Research Center Borstel, Borstel, Germany6German Center for Infection Research, Partner site Hamburg-Lübeck-Borstel-Riemshttps://ror.org/028s4q594, Borstel, Germany7Department of Genetics, University of Cambridge98529https://ror.org/013meh722, Cambridge, United KingdomJared A. Silverman on April 22, 2025 at 7:00 am
In vitro activity of SF001: a next-generation polyene versus amphotericin B
by Roya Vahedi-ShahandashtiCornelia Lass-Flörl1Institute of Hygiene and Medical Microbiology, Medical University of Innsbruck172142https://ror.org/054pv6659, Innsbruck, Tyrol, AustriaAndreas H. Groll on April 22, 2025 at 7:00 am
Efficacy of novel regimens targeting oxidative phosphorylation in Mycobacterium tuberculosis
by Dongshuo LiLiang LiYe ZhangKai ChengWenwen LiangEric NuermbergerXianglong QiLei FuBin WangChenxia YanRui XuYu LuJian Xu1Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute117550https://ror.org/01espdw89, Beijing, China2Department of Medicine, Center for Tuberculosis Research, Johns Hopkins University School of Medicine229384, Baltimore, Maryland, USA3Department of International Health, Johns Hopkins Bloomberg School of Public Health25802, Baltimore, Maryland, USASean Wasserman on April 22, 2025 at 7:00 am
Outcomes after suppressive antimicrobial therapy for prosthetic joint infection: a prospective cohort study
by Craig AboltinsChristopher LemohMani SuleimanAlex SorianoJoshua DavisLaurens Manning1Department of Infectious Diseases, Northern Healthhttps://ror.org/009k7c907, Melbourne, Victoria, Australia2Department of Medicine, Northern Health, The University of Melbourne2281https://ror.org/01ej9dk98, Melbourne, Victoria, Australia3Department of Medicine at Western Health, The University of Melbourne2281https://ror.org/01ej9dk98, Melbourne, Victoria, Australia4Department of Medicine, Monash Health School of Clinical Sciences, Monash University2541https://ror.org/02bfwt286, Melbourne, Victoria, Australia5Research Development and Governance Unit, Northern Healthhttps://ror.org/009k7c907, Melbourne, Victoria, Australia6Research and Industry Engagement, Latrobe University, Melbourne, Victoria, Australia7Department of Infectious Diseases, Hospital Clinic of Barcelona, Barcelona, Spain8IDIBAPS, University of Barcelona16724https://ror.org/021018s57, Barcelona, Spain9Menzies School of Health Research, Charles Darwin University10095https://ror.org/006mbby82, Darwin, Northern Territory, Australia10Department of Infectious Diseases, John Hunter Hospitalhttps://ror.org/0187t0j49, Newcastle, New South Wales, Australia11Department of Infectious Diseases, Fiona Stanley Hospital418838https://ror.org/027p0bm56, Murdoch, Western Australia, Australia12Medical School, Faculty of Health and Medical Sciences, The University of Western Australia172098https://ror.org/047272k79, Perth, Western Australia, AustraliaSarah Doernberg on April 22, 2025 at 7:00 am